MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525456 | Name: Lotrafiban hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lotrafiban hydrochloride is an oral platelet glycoprotein IIb/IIIa blocker.

Chemical Structure

Lotrafiban hydrochloride
Lotrafiban hydrochloride
CAS#179599-82-7

Theoretical Analysis

MedKoo Cat#: 525456

Name: Lotrafiban hydrochloride

CAS#: 179599-82-7

Chemical Formula: C23H33ClN4O4

Exact Mass:

Molecular Weight: 464.99

Elemental Analysis: C, 59.41; H, 7.15; Cl, 7.62; N, 12.05; O, 13.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lotrafiban hydrochloride; Lotrafiban HCl; SB 214857a ; SB-214857-A.
IUPAC/Chemical Name
1H-1,4-Benzodiazepine-2-acetic acid, 7-((4,4'-bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-, monohydrochloride, (2S)-
InChi Key
ZTHSAEXVSBEBHE-BDQAORGHSA-N
InChi Code
InChI=1S/C23H32N4O4.ClH/c1-26-14-18-12-17(2-3-19(18)25-20(23(26)31)13-21(28)29)22(30)27-10-6-16(7-11-27)15-4-8-24-9-5-15;/h2-3,12,15-16,20,24-25H,4-11,13-14H2,1H3,(H,28,29);1H/t20-;/m0./s1
SMILES Code
O=C(O)C[C@@H]1NC2=CC=C(C(N3CCC(C4CCNCC4)CC3)=O)C=C2CN(C)C1=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 464.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29;108(4):399-406. Epub 2003 Jul 21. PubMed PMID: 12874182. 2: Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis. Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):13-25. PubMed PMID: 12769654. 3: Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA. Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb Res. 2001 Jul 15;103(2):143-8. PubMed PMID: 11457472. 4: Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther. 2001 Apr;69(4):210-22. PubMed PMID: 11309549. 5: SoRelle R. SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor. Circulation. 2001 Jan 2;103(1):E9001-2. PubMed PMID: 11191986. 6: Liu F, Craft RM, Morris SA, Carroll RC. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert Opin Investig Drugs. 2000 Nov;9(11):2673-87. Review. PubMed PMID: 11060829. 7: Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation. 2000 Aug 15;102(7):728-35. PubMed PMID: 10942739.

View History

CAY10466

CAY10466

Featured